{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T20:37:20Z","timestamp":1783715840610,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Project of the National Social Science Foundation of China","award":["No. 18XGL019"],"award-info":[{"award-number":["No. 18XGL019"]}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["Xi'an Jiaotong University: xzy022024030"],"award-info":[{"award-number":["Xi'an Jiaotong University: xzy022024030"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s11096-024-01738-6","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T10:01:43Z","timestamp":1715335303000},"page":"1076-1090","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Global trends in pharmacovigilance-related events: a 30-year analysis from the 2019 global burden of disease study"],"prefix":"10.1007","volume":"46","author":[{"given":"Shuzhi","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1937-7951","authenticated-orcid":false,"given":"Bianling","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"issue":"5","key":"1738_CR1","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s43441-022-00415-y","volume":"56","author":"HY Garashi","year":"2022","unstructured":"Garashi HY, Steinke DT, Schafheutle EI. A systematic review of pharmacovigilance systems in developing countries using the WHO pharmacovigilance indicators. Ther Innov Regul Sci. 2022;56(5):717\u201343. https:\/\/doi.org\/10.1007\/s43441-022-00415-y.","journal-title":"Ther Innov Regul Sci"},{"issue":"4","key":"1738_CR2","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1007\/s11096-017-0588-2","volume":"40","author":"S Elshafie","year":"2018","unstructured":"Elshafie S, Roberti AM, Zaghloul I. Pharmacovigilance in developing countries (part II): a path forward. Int J Clin Pharm. 2018;40(4):764\u20138. https:\/\/doi.org\/10.1007\/s11096-017-0588-2.","journal-title":"Int J Clin Pharm"},{"issue":"4","key":"1738_CR3","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/COH.0b013e328354dcac","volume":"7","author":"KA Marcus","year":"2012","unstructured":"Marcus KA, Sorbello A, Truffa M, et al. Current advances in pharmacovigilance in the USA and Europe: meeting the challenges of safety monitoring in HIV. Curr Opin HIV AIDS. 2012;7(4):292\u20138. https:\/\/doi.org\/10.1097\/COH.0b013e328354dcac.","journal-title":"Curr Opin HIV AIDS"},{"issue":"10080","key":"1738_CR4","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/S0140-6736(17)31047-4","volume":"389","author":"LJ Donaldson","year":"2017","unstructured":"Donaldson LJ, Kelley ET, Dhingra-Kumar N, et al. Medication without harm: WHO\u2019s third global patient safety challenge. The Lancet. 2017;389(10080):1680\u20131. https:\/\/doi.org\/10.1016\/S0140-6736(17)31047-4.","journal-title":"The Lancet"},{"issue":"12","key":"1738_CR5","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40264-018-0708-5","volume":"41","author":"A Radecka","year":"2018","unstructured":"Radecka A, Loughlin L, Foy M, et al. Enhancing pharmacovigilance capabilities in the EU regulatory network: the SCOPE joint action. Drug Saf. 2018;41(12):1285\u2013302. https:\/\/doi.org\/10.1007\/s40264-018-0708-5.","journal-title":"Drug Saf"},{"key":"1738_CR6","doi-asserted-by":"publisher","first-page":"e40080","DOI":"10.2196\/40080","volume":"9","author":"J Fossouo Tagne","year":"2023","unstructured":"Fossouo Tagne J, Yakob RA, Dang TH, et al. Reporting, monitoring, and handling of adverse drug reactions in Australia: scoping review. JMIR Public Health Surveill. 2023;9:e40080. https:\/\/doi.org\/10.2196\/40080.","journal-title":"JMIR Public Health Surveill"},{"key":"1738_CR7","unstructured":"Drug Overdose Death Rates. National Institute on Drug Abuse. https:\/\/nida.nih.gov\/research-topics\/trends-statistics\/overdose-death-rates. Accessed 8 March 2024."},{"issue":"10258","key":"1738_CR8","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"T Vos","year":"2020","unstructured":"Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 2020;396(10258):1204\u201322. https:\/\/doi.org\/10.1016\/S0140-6736(20)30925-9.","journal-title":"The Lancet"},{"issue":"10303","key":"1738_CR9","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/S0140-6736(21)01207-1","volume":"398","author":"KR Paulson","year":"2021","unstructured":"Paulson KR, Kamath AM, Alam T, et al. Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019. Lancet. 2021;398(10303):870\u2013905. https:\/\/doi.org\/10.1016\/S0140-6736(21)01207-1.","journal-title":"Lancet"},{"issue":"10062","key":"1738_CR10","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/S0140-6736(16)30388-9","volume":"388","author":"GA Stevens","year":"2016","unstructured":"Stevens GA, Alkema L, Black RE, et al. Guidelines for accurate and transparent health estimates reporting: the GATHER statement. Lancet. 2016;388(10062):e19\u201323. https:\/\/doi.org\/10.1016\/S0140-6736(16)30388-9.","journal-title":"Lancet"},{"key":"1738_CR11","unstructured":"GBD Results. Institute for Health Metrics and Evaluation (IHME). https:\/\/vizhub.healthdata.org\/gbd-results\/. Accessed 8 March 2024."},{"issue":"3","key":"1738_CR12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z","volume":"19","author":"HJ Kim","year":"2000","unstructured":"Kim HJ, Fay MP, Feuer EJ, et al. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335\u201351. https:\/\/doi.org\/10.1002\/(SICI)1097-0258(20000215)19:3%3c335::AID-SIM336%3e3.0.CO;2-Z.","journal-title":"Stat Med"},{"issue":"29","key":"1738_CR13","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1002\/sim.3733","volume":"28","author":"LX Clegg","year":"2009","unstructured":"Clegg LX, Hankey BF, Tiwari R, et al. Estimating average annual per cent change in trend analysis. Stat Med. 2009;28(29):3670\u201382. https:\/\/doi.org\/10.1002\/sim.3733.","journal-title":"Stat Med"},{"issue":"2","key":"1738_CR14","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1080\/03014460.2019.1707872","volume":"47","author":"A Bell","year":"2020","unstructured":"Bell A. Age period cohort analysis: a review of what we should and shouldn\u2019t do. Ann Hum Biol. 2020;47(2):208\u201317. https:\/\/doi.org\/10.1080\/03014460.2019.1707872.","journal-title":"Ann Hum Biol"},{"key":"1738_CR15","unstructured":"Age Period Cohort Web Tool. National Cancer Institute Division of Cancer Epidemiology and Genetics. https:\/\/analysistools.cancer.gov\/apc\/. Accessed 8 March 2024."},{"issue":"11","key":"1738_CR16","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1158\/1055-9965.EPI-14-0300","volume":"23","author":"PS Rosenberg","year":"2014","unstructured":"Rosenberg PS, Check DP, Anderson WF. A web tool for age\u2013period\u2013cohort analysis of cancer incidence and mortality rates. Cancer Epidemiol Biomark Prev. 2014;23(11):2296\u2013302. https:\/\/doi.org\/10.1158\/1055-9965.EPI-14-0300.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"6","key":"1738_CR17","doi-asserted-by":"publisher","first-page":"e1003138","DOI":"10.1371\/journal.pmed.1003138","volume":"17","author":"X Cheng","year":"2020","unstructured":"Cheng X, Yang Y, Schwebel DC, et al. Population ageing and mortality during 1990\u20132017: A global decomposition analysis. Basu S, ed. PLoS Med. 2020;17(6):e1003138. https:\/\/doi.org\/10.1371\/journal.pmed.1003138.","journal-title":"PLoS Med."},{"key":"1738_CR18","doi-asserted-by":"publisher","first-page":"103677","DOI":"10.1016\/j.ajp.2023.103677","volume":"86","author":"J Shen","year":"2023","unstructured":"Shen J, Hua G, Li C, et al. Prevalence, incidence, deaths, and disability-adjusted life-years of drug use disorders for 204 countries and territories during the past 30 years. Asian J Psychiatr. 2023;86:103677. https:\/\/doi.org\/10.1016\/j.ajp.2023.103677.","journal-title":"Asian J Psychiatr"},{"issue":"10258","key":"1738_CR19","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","volume":"396","author":"CJL Murray","year":"2020","unstructured":"Murray CJL, Aravkin AY, Zheng P, et al. Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1223\u201349. https:\/\/doi.org\/10.1016\/S0140-6736(20)30752-2.","journal-title":"Lancet"},{"issue":"2","key":"1738_CR20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1517\/17425255.3.2.147","volume":"3","author":"O Pelkonen","year":"2007","unstructured":"Pelkonen O. Metabolism and pharmacokinetics in children and the elderly. Expert Opin Drug Metab Toxicol. 2007;3(2):147\u20138. https:\/\/doi.org\/10.1517\/17425255.3.2.147.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"9","key":"1738_CR21","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1111\/jgs.17213","volume":"69","author":"BH Han","year":"2021","unstructured":"Han BH, Funk-White M, Ko R, et al. Decreasing perceived risk associated with regular cannabis use among older adults in the United States from 2015 to 2019. J American Geriatrics Society. 2021;69(9):2591\u20137. https:\/\/doi.org\/10.1111\/jgs.17213.","journal-title":"J American Geriatrics Society"},{"issue":"8","key":"1738_CR22","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/s1054-139x(94)90628-9","volume":"15","author":"CV Fletcher","year":"1994","unstructured":"Fletcher CV, Acosta EP, Strykowski JM. Gender differences in human pharmacokinetics and pharmacodynamics. J Adolesc Health. 1994;15(8):619\u201329. https:\/\/doi.org\/10.1016\/s1054-139x(94)90628-9.","journal-title":"J Adolesc Health"},{"issue":"7618","key":"1738_CR23","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1136\/bmj.39323.586123.BE","volume":"335","author":"M Pirmohamed","year":"2007","unstructured":"Pirmohamed M, Atuah KN, Dodoo ANO, et al. Pharmacovigilance in developing countries. BMJ. 2007;335(7618):462\u2013462. https:\/\/doi.org\/10.1136\/bmj.39323.586123.BE.","journal-title":"BMJ"},{"issue":"9110","key":"1738_CR24","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/S0140-6736(97)09038-7","volume":"351","author":"A Dally","year":"1998","unstructured":"Dally A. Thalidomide: Was the tragedy preventable? Lancet. 1998;351(9110):1197\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(97)09038-7.","journal-title":"Lancet"},{"issue":"9","key":"1738_CR25","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.tips.2019.07.005","volume":"40","author":"AO Basile","year":"2019","unstructured":"Basile AO, Yahi A, Tatonetti NP. Artificial intelligence for drug toxicity and safety. Trends Pharmacol Sci. 2019;40(9):624\u201335. https:\/\/doi.org\/10.1016\/j.tips.2019.07.005.","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"1738_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12992-021-00751-y","volume":"17","author":"HY Garashi","year":"2021","unstructured":"Garashi HY, Steinke DT, Schafheutle EI. A qualitative exploration of pharmacovigilance policy implementation in Jordan, Oman, and Kuwait using Matland\u2019s ambiguity-conflict model. Global Health. 2021;17(1):97. https:\/\/doi.org\/10.1186\/s12992-021-00751-y.","journal-title":"Global Health"},{"issue":"8","key":"1738_CR27","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2165\/11536390-000000000-00000","volume":"33","author":"S Olsson","year":"2010","unstructured":"Olsson S, Pal SN, Stergachis A, et al. Pharmacovigilance activities in 55 low- and middle-income countries: a questionnaire-based analysis. Drug Saf. 2010;33(8):689\u2013703. https:\/\/doi.org\/10.2165\/11536390-000000000-00000.","journal-title":"Drug Saf"},{"issue":"7","key":"1738_CR28","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40264-019-00807-4","volume":"42","author":"TM Alshammari","year":"2019","unstructured":"Alshammari TM, Mendi N, Alenzi KA, et al. Pharmacovigilance systems in Arab countries: overview of 22 Arab countries. Drug Saf. 2019;42(7):849\u201368. https:\/\/doi.org\/10.1007\/s40264-019-00807-4.","journal-title":"Drug Saf"},{"issue":"2","key":"1738_CR29","doi-asserted-by":"publisher","first-page":"e001912","DOI":"10.1136\/bmjgh-2019-001912","volume":"5","author":"C Preston","year":"2020","unstructured":"Preston C, Freitas Dias M, Pe\u00f1a J, et al. Addressing the challenges of regulatory systems strengthening in small states. BMJ Glob Health. 2020;5(2):e001912. https:\/\/doi.org\/10.1136\/bmjgh-2019-001912.","journal-title":"BMJ Glob Health"},{"key":"1738_CR30","doi-asserted-by":"publisher","first-page":"106967","DOI":"10.1016\/j.phrs.2023.106967","volume":"197","author":"A Agust\u00ed","year":"2023","unstructured":"Agust\u00ed A, Cereza G, De Abajo FJ, et al. Clinical pharmacology facing the real-world setting: pharmacovigilance, pharmacoepidemiology and the economic evaluation of drugs. Pharmacol Res. 2023;197:106967. https:\/\/doi.org\/10.1016\/j.phrs.2023.106967.","journal-title":"Pharmacol Res"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-024-01738-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-024-01738-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-024-01738-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T08:48:28Z","timestamp":1726217308000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-024-01738-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1738"],"URL":"https:\/\/doi.org\/10.1007\/s11096-024-01738-6","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,10]]},"assertion":[{"value":"24 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}